Trump’s Drug Pricing ‘Dream Team’ And Prospects For Change
Executive Summary
“We’re not looking for a lot of turnover. I think we have a team that works very well together,” HHS Deputy Secretary Eric Hargan said.
You may also be interested in...
Triangulation Or The Bermuda Triangle: Can Trump Work With House Dems On Drug Prices?
President Trump is highlighting drug pricing as an area where he may be able to work with the new Democratic majority in the House. The political wisdom of building common ground on the topic is hard to ignore – but the tempestuous personality of the President is still the overriding factor. Instead, focus on whether HHS can win some breathing room to keep going with administrative changes.
Medicare Part D ‘Modernization’ Policies Still Priority Reforms – OMB’s Grogan
Office of Management and Budget health programs official highlights the Administration’s plan for updating and lowering costs in Medicare Part D, including point-of-sale rebates.
A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?
US FDA Commissioner Gottlieb suggests administrative action to prohibit drug rebates as a way to lower drug prices. His remarks may preview an upcoming proposal from President Trump and HHS Secretary Azar.